Eli Lilly said late Thursday that a range of new data from its migraine portfolio support the potential use of both galcanezumab and lasmiditan as much-needed, new treatment options for patients suffering from migraine. Data will be presented at the American Headache Society Annual Scientific Meeting in Boston.
In particular, the company said it will show phase 3 primary and secondary endpoint data in three late-breaking presentations for galcanezumab for the prevention of episodic and chronic migraine. It will also present late-breaking phase 3 data from a study evaluating the efficacy and safety of lasmiditan for the acute treatment of migraine. Lasmiditan is an oral, first-in-class molecule that could represent the first significant innovation for the acute treatment of migraine in more than two decades.